RTOG 1106/ACRIN 6697, Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator
Feng-Ming (Spring) Kong, MD PhD
Status
Terminated
Date Opened To Accrual
February 22 2012
Date Closed to Accrual
March 08 2017
Date of Study Termination
May 20 2022
Disease Site
Lung [LU]
Non-small Cell Lung Cancer
Phase
II
Developmental Therapeutics
No
Primary Objective
RTOG: To determine whether tumor dose can be escalated to improve the LRPF rate at 2 years when an individualized adaptive radiation treatment (RT) plan is applied by the use of a FDG-PET/CT scan acquired at 40-46 Gy initial dose of RT in patients with inoperable or unresectable stage III NSCLC
ACRIN: To determine whether the relative change in SUV/peak from the baseline to the during-treatment FDG-PET/CT, defined as (during-treatment SUVpeak - baseline SUVpeak) baseline SUVpeak X 100%, can predict the LRPF with a 2-year follow up.
See "ACRIN Information" in the left column of this page.
RT Credentialing: Please see section 5 for specific details
Lung Atlas
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Patient Population
Patients with FDG-avid and histologically or cytologically proven AJCC stage IIIA or IIIB, non-operable NSCLC
Target Accrual
138
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.